APA (7th ed.) Citation

Marmé, F. (2018). Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. Cancer chemotherapy and pharmacology, 81(4), . https://doi.org/10.1007/s00280-018-3540-9

Chicago Style (17th ed.) Citation

Marmé, Frederik. "Phase 1, Open-label, Dose-escalation Study of Sorafenib in Combination with Eribulin in Patients with Advanced, Metastatic, or Refractory Solid Tumors." Cancer Chemotherapy and Pharmacology 81, no. 4 (2018). https://doi.org/10.1007/s00280-018-3540-9.

MLA (9th ed.) Citation

Marmé, Frederik. "Phase 1, Open-label, Dose-escalation Study of Sorafenib in Combination with Eribulin in Patients with Advanced, Metastatic, or Refractory Solid Tumors." Cancer Chemotherapy and Pharmacology, vol. 81, no. 4, 2018, https://doi.org/10.1007/s00280-018-3540-9.